![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, January 2001, p. 327-330, Vol. 45, No. 1
Division of Infectious Diseases, Department
of Internal Medicine, Center for the Study of Emerging and
Reemerging Pathogens, University of Texas Medical School, Houston,
Texas 77030
Received 5 June 2000/Returned for modification 11 July
2000/Accepted 18 October 2000
We investigated the relevance of prominent reduction in turbidity
macroscopically (MIC) and formation of aberrant hyphal tips microscopically (minimum effective concentration; MEC) in measuring the
in vitro activity of caspofungin against Aspergillus and
Fusarium. Caspofungin generated low MICs and MECs against
Aspergillus, but not for Fusarium. While MICs
increased inconsistently when the incubation time was prolonged, MEC
appeared as a stable and potentially relevant endpoint in testing in
vitro caspofungin activity.
The echinocandins are a group
of lipopeptide antifungal agents that contain a cyclic
hexapeptide nucleus and act via inhibition of
(1,3)- A reproducible and clinically relevant method for susceptibility
testing of echinocandins has not been fully established yet. One of the
undetermined test parameters is the MIC endpoint to be used for
measuring the in vitro activity. Echinocandins exhibit fungicidal or
fungistatic activity against Candida spp. (8, 9). The MICs of echinocandins for Candida have been
determined so far as either the least concentration of the drug that
produces 100% inhibition of growth (21, 22) or that
producing 80% reduction in turbidity (9, 13).
Testing the in vitro activity of echinocandins against
Aspergillus spp. is more complicated.
Echinocandins are active against Aspergillus both in
vitro (5, 10, 20) and in vivo (1, 16).
However, the assessment of in vitro activity requires distinct evaluation. Instead of a complete macroscopic growth inhibition, partial inhibition is seen in which the fungus microscopically produces
short, stubby, and highly branched hyphae (6, 9, 16).
Kurtz et al. (16) proposed that the drug concentration at
which these morphological changes were first observed be called the
minimum effective concentration (MEC). Nevertheless, neither the proper
method to be used for the detection of the in vitro activity of
caspofungin and other echinocandins against molds (5, 10,
20) nor the clinical significance of MEC has been fully defined.
This study was designed to comparatively evaluate the two endpoints,
MIC and MEC, in the determination of the in vitro activity of
caspofungin against clinical Aspergillus and
Fusarium isolates. The effect of incubation period and test
media on both MIC and MEC was also investigated.
(This work was presented in part at the 39th Interscience
Conference on Antimicrobial Agents and Chemotherapy, 26 to 29 September 1999, in San Francisco, Calif., as abstr.
no. J-160.)
The test organisms were comprised of 82 Aspergillus
and 22 Fusarium strains. Two itraconazole-resistant
A. fumigatus strains, kindly provided by D. W. Denning, were also included (7). Each isolate was tested
in duplicate. One of the clinical isolates (strain no. 2-160; A. fumigatus) was included in each run for quality control.
Caspofungin was provided by Merck Research Laboratories (Rahway, N.J.)
as a standard powder and tested in concentrations of 0.03125 to 16 µg/ml. Except as noted, susceptibility tests were performed according
to the NCCLS M38-P microdilution methodology (18).
In addition to the reference RPMI 1640 medium (RPMI; Sigma Chemical
Co., St. Louis, Mo.), RPMI supplemented to 2% glucose (RPMI-2) and
Antibiotic Medium 3 (BBL/Becton Dickinson lot JD4ZSG) buffered by
adding 1 g of Na2HPO4 and 1 g of
NaH2PO4 to each liter and supplemented to
2% glucose (AM3) were also used as test media.
Microdilution plates were prepared in bulk and stored at The plates were incubated at 35°C and the MIC results were read
visually at 24, 48, and 72 h as the least concentration of drug
that produced a prominent decrease in turbidity. MEC values were
determined by microscopic examination of the microdilution plates. The
least concentration of caspofungin causing abnormal hyphal growth with
short abundant branchings was defined as the MEC (2, 16).
The geometric mean (GM) and the ranges of MICs and MECs were analyzed
to evaluate the in vitro activity of caspofungin. For computation of
the GM values, high offscale MICs and MECs were converted to the
twofold concentration just above the highest tested drug concentration.
GMs and ranges for the observed MIC and MEC values at 24, 48, and
72 h in RPMI, RPMI-2, and AM3 are shown in Tables
1, 2, and
3, respectively. In general, caspofungin
MICs had a tendency to increase by one to five twofold dilutions at 48 and 72 h, compared to the 24-h MIC reading. MEC readings tended to
be stable over this time period. Growth at 24 h was
sufficient to permit reading an endpoint for all species but
A. nidulans. Based on both MIC and MEC measurements,
caspofungin did not have any meaningful activity against
Fusarium isolates.
0066-4804/01/$04.00+0 DOI: 10.1128/AAC.45.1.327-330.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
In Vitro Susceptibility Testing Methods for
Caspofungin against Aspergillus and
Fusarium Isolates
ABSTRACT
Top
Abstract
Text
References
TEXT
Top
Abstract
Text
References
-D-glucan synthase. Novel echinocandins, including
LY303366, L-733,560, and caspofungin (formerly referred to as MK-0991
and as L-743,872) (1, 4, 5, 9-12, 15, 17, 19, 21-24) are
currently under investigation.
70°C until
use. In order to assure that caspofungin remains stable in
microdilution plates stored at 70°C, stability control tests were
performed initially. For this purpose, four quality control strains
previously tested in our laboratory several times for caspofungin
susceptibility were chosen (5W31 [C. lusitaniae], CL524 [C. lusitaniae], UTR-14 [C. albicans],
and 707-13 [C. albicans], with caspofungin MICs at
24 h of 2, 2, 0.5, and 0.5 µg/ml, respectively). Caspofungin
dilutions were prepared in microdilution plates using the test media,
and the first susceptibility tests were performed on the same day.
Keeping the plates at 70°C in the interim, this initial test was
followed by its repetitions performed at 24 and 48 h and at 8, 9, 13, and 21 days following the day of plate preparation. MICs were read
visually after both 24 and 48 h of incubation. The analysis of the
data showed that, for each individual isolate, the MICs at 21 days
either remained the same or changed by at most one twofold dilution
compared to those obtained on the day of plate preparation. Based on
these results, the plates were prepared in bulk and kept at 70°C
until use but never longer than 21 days. Likewise, since the plates are
incubated at 35°C for 48 h during susceptibility testing, the
stability of caspofungin at 35°C was also investigated. For this
purpose, the susceptibility tests performed at day 0 were repeated
after the plates were stored at 35°C for 24 and 48 h. As with
the long-term storage studies, the MICs did not vary more than one
twofold dilution. These data show that caspofungin is stable both prior
to and during the studies under the test conditions.
TABLE 1.
MIC and MEC values obtained in RPMI after 24, 48, and
72 h of incubation
TABLE 2.
MIC and MEC values obtained in RPMI-2 after 24, 48, and 72 h of incubation
TABLE 3.
MIC and MEC values obtained in AM3 after 24, 48, and
72 h of incubation
Among Aspergillus species, A. flavus yielded the highest MICs after 24 h in all test media, followed by A. fumigatus. However, the 48-h MICs obtained in RPMI and RPMI-2 for A. fumigatus were higher than those for A. flavus. On the other hand, all Aspergillus species generated similarly low MEC values. The itraconazole-resistant isolates had the same MIC and MEC values as other isolates of their species. Compared to RPMI, RPMI-2 gave slightly higher and AM3 generated slightly lower MICs and MECs for both Aspergillus and Fusarium spp. This effect was most pronounced with the MIC readings at 24 h.
MIC and MEC values were most similar at 24 h, but the correlation was limited overall. The MEC for A. flavus was 10-fold lower than the MIC at this time, and the MEC for A. fumigatus was approximately 3-fold lower than the MIC. As the incubation time was extended to 48 and 72 h, the discrepancies between the corresponding MIC and MEC values increased. The morphological changes seen at the MEC were relatively less affected by incubation time and did not vary more than one twofold dilution. On the other hand, MICs increased over time, but not in a consistent or predictable fashion.
Of note, a macroscopic (visible to the naked eye) correlate of the microscopic MEC was observed. At concentrations of caspofungin below the MEC, the colonies had a visibly filamentous growth pattern. At and above the MEC, the colonies became less filamentous and more granular. Thus, with practice it was possible to determine the MEC without the use of microscopic examination.
Data reported thus far on the activity of caspofungin against
Aspergillus and Fusarium spp. are limited.
Pfaller et al. (20) used the NCCLS microdilution
methodology and reported MIC90 values after 72 h
of incubation of 0.12 and 16 µg/ml, for Aspergillus and
Fusarium, respectively, using an MIC endpoint of
approximately 75% reduction in growth. Del Poeta et al.
(5) used the macrodilution methodology proposed by
NCCLS for yeasts (M27-A), an inoculum size of (0.5 to 2.5) × 103 CFU/ml, and an MIC defined as the lowest drug
concentration yielding visual turbidity less than or equal to that
corresponding to 80% inhibition of growth. MICs were read when
adequate growth was evident for each individual isolate. The GM MICs
were 0.2, 
0.09, and 75.78 µg/ml for A. flavus,
A. fumigatus, and F. oxysporum, respectively. The values reported in both of these studies are lower than what we observed for Aspergillus but similar for
Fusarium. Espinel-Ingroff (10) defined the MIC
as prominent inhibition of growth (50% of that of the growth
control) and reported higher MIC values for A. fumigatus (GM
of 2.15 µg/ml), lower values for A. flavus (0.5 µg/ml),
and similar values for both A. terreus (0.5 µg/ml) and
Fusarium spp. (
16 µg/ml) in comparison to our results.
We also explored in detail the possible value of the MEC and its correlation with the MIC. Very few reports to date have used the MEC measurement. For A. flavus and A. fumigatus isolates, pneumocandin A0 and pneumocandin B0 MECs of 0.015 to 2 µg/ml (16) and LY-303366 MECs of 0.00125 to 0.005 µg/ml were reported (26). Whether the MEC has greater clinical relevance than the MIC has yet to be determined, but we think that the stability of the MEC measurement might make it a more reproducible endpoint to be used. Across multiple times of reading and medium conditions, the MEC values generally varied less than three twofold dilutions, while the MIC readings changed significantly and without obvious pattern as the incubation period was extended beyond 24 h.
The MEC is clearly a more labor-intensive measurement. We did, however, observe that the morphological changes observed microscopically are reflected in the macroscopic growth pattern. At and above the MEC, the abnormal hyphal structures yield colonies that are less filamentous and more granular. With experience, it did become possible to visually estimate the MEC. This, however, seemed to require considerable practice, and the interobserver reproducibility of this approach will require further study.
We also investigated the effect of time and medium on MIC and MEC. MICs generated in RPMI-2 were higher than those generated in RPMI, whereas AM3 tended to lower the values. Testing in AM3 has been shown to reduce the MIC of Candida isolates for both amphotericin B (25) and caspofungin (19). In other testing of Aspergillus and Fusarium isolates, we have shown that RPMI-2 MICs are higher than RPMI MICs for itraconazole and voriconazole and that AM3 MICs are lower for amphotericin B (3). Overall, these media effects are slight and have unclear meaning. In addition to the MICs, it has also been shown that the killing activity of LY303366 is influenced by the test medium used. The use of AM3 as the test medium instead of RPMI resulted in not only a significant decline in MICs but also in a more rapid fungicidal activity against Candida (13, 14).
The two itraconazole-resistant A. fumigatus isolates included in the study behaved similarly to others in terms of both caspofungin MICs and MECs. This finding is not unexpected, since the mechanisms of action for azoles and echinocandin antifungal agents are entirely distinct.
We conclude that MEC appears as a stable in vitro measurement for determining the activity of caspofungin against molds. Demonstration of its in vivo relevance awaits further studies.
| |
ACKNOWLEDGMENTS |
|---|
This study was supported by a grant to Sevtap Arikan from Turkish Scientific and Technical Research Council (TUBITAK) and by a grant from Merck Research Laboratories.
| |
FOOTNOTES |
|---|
* Corresponding author. Present address: Hacettepe University Medical School, Department of Microbiology and Clinical Microbiology, 06100 Ankara, Turkey. Phone: 90-312-3051562. Fax: 90-312-3115250. E-mail: sarikan{at}metu.edu.tr.
| |
REFERENCES |
|---|
|
Top
Abstract
Text
References
|
|---|
| 1. | Abruzzo, G. K., A. M. Flattery, C. J. Gill, L. Kong, J. G. Smith, V. B. Bikounis, J. M. Balkovec, A. F. Bouffard, J. F. Dropinski, H. Rosen, H. Kropp, and K. Bartizal. 1997. Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis. Antimicrob. Agents Chemother. 41:2333-2338[Abstract]. |
| 2. | Abruzzo, G. K., A. M. Flattery, C. J. Gill, L. Kong, J. G. Smith, D. Krupa, V. B. Pkounis, H. Kropp, and K. Bartizal. 1995. Evaluation of water-soluble pneumocandin analogs L-733560, L-705589, and L-731373 with mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis. Antimicrob. Agents Chemother. 39:1077-1081[Abstract]. |
| 3. |
Arikan, S.,
M. Lozano-Chiu,
V. Paetznick,
S. Nangia, and J. H. Rex.
1999.
Microdilution susceptibility testing of amphotericin B, itraconazole, and voriconazole against clinical isolates of Aspergillus and Fusarium species.
J. Clin. Microbiol.
37:3946-3951 |
| 4. | Bartizal, K., C. J. Gill, G. K. Abruzzo, A. M. Flattery, L. Kong, P. M. Scott, J. G. Smith, C. E. Leighton, A. Bouffard, J. F. Dropinski, and J. Balkovec. 1997. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob. Agents Chemother. 41:2326-2332[Abstract]. |
| 5. | Del Poeta, M., W. A. Schell, and J. R. Perfect. 1997. In vitro antifungal activity of pneumocandin L-743,872 against a variety of clinically important molds. Antimicrob. Agents Chemother. 41:1835-1836[Abstract]. |
| 6. |
Denning, D. W.
1997.
Echinocandins and pneumocandins a new antifungal class with a novel mode of action.
J. Antimicrob. Chemother.
40:611-614 |
| 7. |
Denning, D. W.,
S. A. Radford,
K. L. Oakley,
L. Hall,
E. M. Johnson, and D. W. Warnock.
1997.
Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection.
J. Antimicrob. Chemother.
40:401-414 |
| 8. | Ernst, E. J., M. E. Klepser, M. E. Ernst, S. A. Messer, and M. A. Pfaller. 1999. In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods. Diagn. Microbiol. Infect. Dis. 33:75-80[CrossRef][Medline]. |
| 9. | Ernst, M. E., M. E. Klepser, E. J. Wolfe, and M. A. Pfaller. 1996. Antifungal dynamics of LY 303366, an investigational echinocandin B analog, against Candida spp. Diagn. Microbiol. Infect. Dis. 26:125-131[CrossRef][Medline]. |
| 10. |
Espinel-Ingroff, A.
1998.
Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts.
J. Clin. Microbiol.
36:2950-2956 |
| 11. | Franzot, S. P., and A. Casadevall. 1997. Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro. Antimicrob. Agents Chemother. 41:331-336[Abstract]. |
| 12. | Graybill, J. R., L. K. Najvar, M. F. Luther, and A. W. Fothergill. 1997. Treatment of murine disseminated candidiasis with L-743, 872. Antimicrob. Agents Chemother. 41:1775-1777[Abstract]. |
| 13. |
Klepser, M. E.,
E. J. Ernst,
M. E. Ernst,
S. A. Messer, and M. A. Pfaller.
1998.
Evaluation of endpoints for antifungal susceptibility determinations with LY303366.
Antimicrob Agents Chemother.
42:1387-1391 |
| 14. | Klepser, M. E., E. J. Ernst, M. E. Ernst, and M. A. Pfaller. 1997. Growth medium effect on the antifungal activity of LY 303366. Diagn. Microbiol. Infect. Dis. 29:227-31[CrossRef][Medline]. |
| 15. | Krishnarao, T. V., and J. N. Galgiani. 1997. Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans. Antimicrob. Agents Chemother. 41:1957-1960[Abstract]. |
| 16. |
Kurtz, M. B.,
I. B. Heath,
J. Marrinan,
S. Dreikorn,
J. Onishi, and C. Douglas.
1994.
Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)--D-glucan synthase.
Antimicrob. Agents Chemother.
38:1480-1489 |
| 17. | Martinez-Suarez, J. V., and J. L. Rodriguez-Tudela. 1996. In vitro activities of semisynthetic pneumocandin L-733,560 against fluconazole-resistant and -susceptible Candida albicans isolates. Antimicrob Agents Chemother. 40:1277-1279[Abstract]. |
| 18. | National Committee for Clinical Laboratory Standards. 1998. Reference method for broth dilution antifungal susceptibility testing of conidium-forming filamentous fungi. Proposed standard. NCCLS document M38-P. National Committee for Clinical Laboratory Standards, Wayne, Pa. |
| 19. | Nelson, P. W., M. Lozano-Chiu, and J. H. Rex. 1997. In vitro growth-inhibitory activity of pneumocandins L-733,560 and L-743,872 against putatively amphotericin B- and fluconazole-resistant Candida isolates: influence of assay conditions. J. Med. Vet. Mycol. 35:285-287[Medline]. |
| 20. | Pfaller, M. A., F. Marco, S. A. Messer, and R. N. Jones. 1998. In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. Diagn. Microbiol. Infect. Dis. 30:251-255[CrossRef][Medline]. |
| 21. | Pfaller, M. A., S. A. Messer, and S. Coffman. 1997. In vitro susceptibilities of clinical yeast isolates to a new echinocandin derivative, LY303366, and other antifungal agents. Antimicrob. Agents Chemother. 41:763-766[Abstract]. |
| 22. |
Pfaller, M. A.,
S. A. Messer,
S. Gee,
S. Joly,
C. Pujol,
D. J. Sullivan,
D. C. Coleman, and D. R. Soll.
1999.
In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents.
J. Clin. Microbiol.
37:870-872 |
| 23. | Uzun, O., S. Kocagoz, Y. Cetinkaya, S. Arikan, and S. Unal. 1997. In vitro activity of a new echinocandin, LY303366, compared with those of amphotericin B and fluconazole against clinical yeast isolates. Antimicrob. Agents Chemother. 41:1156-1157[Abstract]. |
| 24. | Vazquez, J. A., M. Lynch, D. Boikov, and J. D. Sobel. 1997. In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species. Antimicrob. Agents Chemother. 41:1612-1614[Abstract]. |
| 25. | Wanger, A., K. Mills, P. W. Nelson, and J. H. Rex. 1995. Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution method for antifungal susceptibility testing: enhanced ability to detect amphotericin B-resistant Candida isolates. Antimicrob. Agents Chemother. 39:2520-2522[Abstract]. |
| 26. | Zhanel, G. G., J. A. Karlowsky, G. A. J. Harding, T. V. Balko, S. A. Zelenitsky, M. Friesen, A. Kabani, M. Turik, and D. J. Hoban. 1997. In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species. Antimicrob. Agents Chemother. 41:863-865[Abstract]. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Clin. Vaccine Immunol. | Clin. Microbiol. Rev. |
|---|---|
| J. Clin. Microbiol. | ALL ASM JOURNALS |
